Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Article
  • Special Issue: Current evidence and perspectives for hypertension management in Asia
  • Published:

A novel clinical-imaging nomogram for predicting primary aldosteronism in patients with hypertension

Hypertension Research volume 46, pages 2603–2612 (2023)Cite this article

Abstract

This study aimed to develop and validate the accuracy of a clinical-imaging index nomogram in predicting primary aldosteronism (PA) in patients with hypertension. This case-control study enrolled 404 hypertension patients in the First Affiliated Hospital of Nanjing Medical University, China, from April 2017 to September 2021. The patients were randomly divided into the training set (n = 283, 70%) and the validation set (n = 121, 30%). Univariate and multivariate logistic regression analyses were performed to identify independent predictors of PA, which were then used construct a nomogram. The receiver operating characteristic (ROC) curve and calibration plot were drawn to assess the predictive value. The accuracies of our nomogram and other known prediction models were compared using decision curve analyses (DCA). Four significant variables (history of hypokalemia [OR = 2.684, 95% CI: 1.281–5.623, P < 0.001], typical imaging feature [OR = 2.316, 95% CI: 1.166–4.601, P = 0.003], 24 h urine potassium [OR = 0.956, 95% CI: 0.932–0.980, P < 0.001], plasma renin activity [PRA] [OR = 1.423, 95% CI: 1.161–1.744, P < 0.001]) in the multivariate logistic regression analysis were sifted out, and used to build the nomogram. The predictive nomogram yielded an AUC of 0.890 (95% CI, 0.853–0.927) in the training set and 0.860 (95% CI, 0.793–0.927) in the validation set. Predicted and actual probability of PA matched well in the nomogram. Moreover, the DCA showed that the nomogram gained a net benefit in clinical practice in predicting PA when the threshold value was set between 0.1 and 1.0. Our four-variable nomogram was accurate in predicting PA patients and might be introduced into clinical management.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1
Fig. 2
Fig. 3
Fig. 4

References

  1. Yang Y, Reincke M, Williams TA. Prevalence, diagnosis and outcomes of treatment for primary aldosteronism. Best Pract Res Clin Endocrinol Metab. 2020;34:101365.

    Article  CAS  PubMed  Google Scholar 

  2. Funder JW, Carey RM, Mantero F, Murad MH, Reincke M, Shibata H, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2016;101:1889–916.

    Article  CAS  Google Scholar 

  3. Mulatero P, Monticone S, Bertello C, Viola A, Tizzani D, Iannaccone A, et al. Long-term cardio- and cerebrovascular events in patients with primary aldosteronism. J Clin Endocrinol Metab. 2013;98:4826–33.

    Article  CAS  Google Scholar 

  4. Vaidya A, Carey RM. Evolution of the primary aldosteronism syndrome: updating the approach [published correction appears in J Clin Endocrinol Metab. 2021 Jan 1;106(1):e414]. J Clin Endocrinol Metab. 2020;105:3771–83.

    Article  PubMed Central  Google Scholar 

  5. Balachandran VP, Gonen M, Smith JJ, DeMatteo RP. Nomograms in oncology: more than meets the eye. Lancet Oncol. 2015;16:e173–e180.

    Article  PubMed Central  Google Scholar 

  6. Chinese Society of Endocrinology. Expert consensus on the diagnosis and treatment of primary aldosteronism (2020). Chin J Endocrinol Metab. 2020;36:727–36.

    Google Scholar 

  7. Young WF Jr. Diagnosis and treatment of primary aldosteronism: practical clinical perspectives. J Intern Med. 2019;285:126–48.

    Article  Google Scholar 

  8. Yamashita T, Shimizu S, Koyama M, Ohno K, Mita T, Tobisawa T, et al. Screening of primary aldosteronism by clinical features and daily laboratory tests: combination of urine pH, sex, and serum K. J Hypertens. 2018;36:326–34.

    Article  CAS  PubMed  Google Scholar 

  9. Ganguly A. Primary aldosteronism. N Engl J Med. 1998;339:1828–34.

    Article  CAS  PubMed  Google Scholar 

  10. Sang X, Jiang Y, Wang W, Yan L, Zhao J, Peng Y, et al. Prevalence of and risk factors for primary aldosteronism among patients with resistant hypertension in China. J Hypertens. 2013;31:1465–72.

    Article  CAS  PubMed  Google Scholar 

  11. Mulatero P, Monticone S, Deinum J, Amar L, Prejbisz A, Zennaro MC, et al. Genetics, prevalence, screening and confirmation of primary aldosteronism: a position statement and consensus of the Working Group on Endocrine Hypertension of The European Society of Hypertension. J Hypertens. 2020;38:1919–28.

    Article  CAS  PubMed  Google Scholar 

  12. Jędrusik P, Symonides B, Wojciechowska E, Gryglas A, Gaciong Z. Diagnostic value of potassium level in a spot urine sample as an index of 24-hour urinary potassium excretion in unselected patients hospitalized in a hypertension unit. PLoS ONE. 2017;12:e0180117.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Yin GS, Zhang SL, Yan L, Li F, Qi YQ, Chen ZC, et al. New index of using serum sodium and potassium and urine sodium and potassium jointly in screening primary aldosteronism in hypertensive patients. Zhonghua Yi Xue Za Zhi. 2010;90:962–6.

    CAS  PubMed  Google Scholar 

  14. Zheng FF, Zhu LM, Nie AF, Li XY, Lin JR, Zhang K, et al. Clinical characteristics of somatic mutations in Chinese patients with aldosterone-producing adenoma. Hypertension. 2015;65:622–8.

    Article  CAS  PubMed  Google Scholar 

  15. Yang Y, Gomez-Sanchez CE, Jaquin D, Aristizabal Prada ET, Meyer LS, Knösel T, et al. Primary aldosteronism: KCNJ5 mutations and adrenocortical cell growth. Hypertension. 2019;74:809–16.

    Article  CAS  PubMed  Google Scholar 

  16. He K, Zhang ZT, Wang ZH, Wang Y, Wang YX, Zhang HZ, et al. A clinical-radiomic nomogram based on unenhanced computed tomography for predicting the risk of aldosterone-producing adenoma. Front Oncol. 2021;11:634879.

    Article  CAS  PubMed Central  Google Scholar 

  17. Yozamp N, Hundemer GL, Moussa M, Underhill J, Fudim T, Sacks BA, et al. Intraindividual variability of aldosterone concentrations in primary aldosteronism: implications for case detection. Hypertension. 2021;77:891–9.

    Article  CAS  PubMed  Google Scholar 

  18. Liu YQ, Wang M, Qiu XT, Ma GD, Ji MY, Sun M. Research of positive screening rates for primary aldosteronism. J Nanjing Med Univ (Nat Sci). 2022;42:1426–31.

    Google Scholar 

  19. Hong YN, Sun F, Zhang HX, Liu XL, Zhao ZG, He HB, et al. Diagnostic efficacy of chemiluminescence immunoassay versus radioimmunoassay in screening primary aldosteronism. J Army Med Univ. 2019;41:2080–6.

    Google Scholar 

  20. Lai FH, Cao XP, Lin HM, Zhang HL, Fu J, Xiao HP, et al. Comparison of plasma renin and aldosterone measured by radioimmunoassay and chemiluminescence immunoassay in screening primary aldosteronism. Chin J Hypertens. 2015;23:150–3.

    CAS  Google Scholar 

  21. Liu Z, Zhang M, Ren Y, Chen T, Gao HJ, He H, et al. Performance verification of plasma renin and aldosterone examination with chemiluminescence immunoassay and its screening efficacy for primary aldosteronism. J Sichuan Univ (Med Sci). 2021;52:472–6.

    Google Scholar 

  22. Kietsiriroje N, Wonghirundecha R, Suntornlohanakul O, Murray RD. Construction of a predictive scoring system as a guide to screening and confirmation of the diagnosis of primary aldosteronism. Clin Endocrinol. 2020;92:196–205.

    Article  CAS  Google Scholar 

  23. Hanslik G, Wallaschofski H, Dietz A, Riester A, Reincke M, Allolio B, et al. Increased prevalence of diabetes mellitus and the metabolic syndrome in patients with primary aldosteronism of the German Conn’s Registry. Eur J Endocrinol. 2015;173:665–75.

    Article  CAS  PubMed  Google Scholar 

  24. Akehi Y, Yanase T, Motonaga R, Umakoshi H, Tsuiki M, Takeda Y, et al. High prevalence of diabetes in patients with primary aldosteronism (PA) associated with subclinical hypercortisolism and prediabetes more prevalent in bilateral than unilateral PA: A Large, Multicenter Cohort Study in Japan. Diabetes Care. 2019;42:938–45.

    Article  CAS  PubMed  Google Scholar 

  25. Liu Y, Zhou L, Liu Z, Ma Y, Lin L, Zhu Y, et al. Higher blood urea nitrogen and urinary calcium: new risk factors for diabetes mellitus in primary aldosteronism patients. Front Endocrinol. 2020;11:23.

    Article  Google Scholar 

  26. Wang MH, Li NF, Luo Q, Wang GL, Heizhati M, Wang L, et al. Development and validation of a novel diagnostic nomogram model to predict primary aldosteronism in patients with hypertension. Endocrine. 2021;73:682–92.

    Article  CAS  Google Scholar 

  27. Lin W, Gan W, Feng P, Zhong L, Yao Z, Chen P, et al. Online prediction model for primary aldosteronism in patients with hypertension in Chinese population: a two-center retrospective study. Front Endocrinol. 2022;13:882148.

    Article  Google Scholar 

Download references

Acknowledgements

We are grateful to all the patients for their participation.

Funding

This study was funded by the 4th Batch of Special Grants of China Postdoctoral Science Foundation (front of the Station) (2022TQ0132); Natural Science Foundation of Jiangsu Basic Research Program-Youth Foundation (BK20220717).

Author information

Authors and Affiliations

  1. Department of Endocrinology and Metabolism, the First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China

    Yuqing Liu, Min Wang, Xueting Qiu, Guodong Ma, Mingyu Ji, Yuhong Yang & Min Sun

Authors
  1. Yuqing Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Min Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Xueting Qiu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Guodong Ma
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mingyu Ji
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yuhong Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Min Sun
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Min Sun.

Ethics declarations

Conflict of interest

The authors declare no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Liu, Y., Wang, M., Qiu, X. et al. A novel clinical-imaging nomogram for predicting primary aldosteronism in patients with hypertension. Hypertens Res 46, 2603–2612 (2023). https://doi.org/10.1038/s41440-023-01374-z

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41440-023-01374-z

Keywords

This article is cited by

Search

Advanced search

Quick links